Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest electroporation Stories

2012-06-26 02:27:18

SAN DIEGO, June 26, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), a company developing the OncoSec Medical System (OMS) ElectroOncology therapies to treat advanced-stage solid tumors, announced that Dr. Adil Daud, principal investigator, presented preliminary enrollment and safety data at the Second European Post-Chicago Melanoma Meeting in Munich, Germany for the company's on-going Phase II metastatic melanoma clinical trial, OMS-I100. (Logo:...

2012-03-26 18:44:30

Innovative interventional radiology procedure zaps around complicated pancreatic tumors, improving prognosis and pancreatic cancer treatment paradigm Results of a study presented at the Society of Interventional Radiology's 37th Annual Scientific Meeting in San Francisco, Calif., signal a light at the end of the tunnel for individuals with inoperable locally advanced pancreatic cancer (LAPC). A new procedure called irreversible electroporation or IRE uses microsecond electrical pulses to...

2012-03-13 03:00:00

BLUE BELL, Pa., March 13, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX®-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects. These interim results were presented by Dr. Niranjan Y. Sardesai, Inovio's Chief Operating Officer, at the Vaccine World Summit 2012 in Hyderabad, India in a...

2012-02-28 05:01:00

SAN DIEGO, Feb. 28, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Investigational Review Board (IRB) approval has been received by the University of California San Francisco and the first patient has been dosed for a Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of advanced...

2012-02-22 03:00:00

BLUE BELL, Pa., Feb. 22, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that its next generation surface skin electroporation technology was successfully used to significantly enhance the delivery of small interfering RNA (siRNA) molecules to skin in animal studies. The data was published in the journal Molecular Therapy - Nucleic Acids in a paper entitled, "Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface...

2011-11-17 03:00:00

BLUE BELL, Pa., Nov. 17, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon® avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines. This...

2011-11-15 23:00:00

MADISON, Wis., Nov. 16, 2011 /PRNewswire/ -- Ideal for transfecting cells propagated in 3D cell culture, the new 3D Transfection System combines the technologies of Reinnervate's alvetex® 3D cell culture plates and Mirus Bio's TransIT®-3D Transfection Reagent, enabling scientists to conduct research that more accurately mimics the tissue environment. (Logo: http://photos.prnewswire.com/prnh/20100818/CG52502LOGO) Under the agreement, Mirus will produce...

2011-09-26 13:46:00

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology(TM) therapies to treat solid tumor cancers, announced today clinical study results presented at the Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec's exhibition highlighted a poster titled, "OMS ElectroChemotherapy: Targeted Ablation of Solid Tumors using Reversible Electroporation in...

2011-09-26 05:01:00

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology(TM) therapies to treat solid tumor cancers, announced today clinical study results presented at the Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec's exhibition highlighted a poster titled, "OMS ElectroChemotherapy: Targeted Ablation of Solid Tumors using Reversible Electroporation in...